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Separate lines of evidence have demonstrated the involvement of N-methyl-D-aspartate
(NMDA) receptor and oligodendrocyte dysfunctions in schizophrenia. Here, we have
carried out shotgun mass spectrometry proteome analysis of oligodendrocytes treated
with the NMDA receptor antagonist MK-801 to gain potential insights into these
effects at the molecular level. The MK-801 treatment led to alterations in the levels
of 68 proteins, which are associated with seven distinct biological processes. Most
of these proteins are involved in energy metabolism and many have been found to
be dysregulated in previous proteomic studies of post-mortem brain tissues from
schizophrenia patients. Finally, addition of the antipsychotic clozapine to MK-801-
treated oligodendrocyte cultures resulted in changes in the levels of 45 proteins and
treatment with clozapine alone altered 122 proteins and many of these showed opposite
changes to the MK-801 effects. Therefore, these proteins and the associated energy
metabolism pathways should be explored as potential biomarkers of antipsychotic
efficacy. In conclusion, MK-801 treatment of oligodendrocytes may provide a useful
model for testing the efficacy of novel treatment approaches.
Keywords: glial cells, oligodendrocyte, proteomics, schizophrenia, pharmacology, clozapine, MK801
INTRODUCTION
The N-methyl-D-aspartate receptor (NMDAr) is an ionotropic receptor activated by glutamate,
allowing the non-selective influx of calcium and sodium and outflow of potassium. The function
of NMDAr in neurons is well-described as it participates actively on glutamatergic transmission,
which is known to be defective in schizophrenia and related psychiatric disorders.
Schizophrenia presents with a variety of both positive and negative symptoms (Lewis, 2000).
There are also disturbances in cognitive processes, such as attention and working memory, which
can appear prior to the onset of the clinical condition. These cognitive problems represent core
features of the illness and are associated to NMDAr dysfunction (Hahn et al., 2006). NMDAr
antagonists exacerbate pre-existing symptoms in patients with schizophrenia and may drive
schizophrenia-like symptoms in healthy mice and human volunteers (Gunduz-Bruce, 2009).
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Moreover, these antagonists have been found to trigger sensory
and motor disturbances in rats, similar to those displayed by
patients with schizophrenia (Kovacic and Somanathan, 2010). At
the cellular level, treatment with NMDAr antagonists have been
shown to cause neuronal degeneration in retrosplenial, pyriform,
and entorhinal cortices, as well as the tenia tecti amygdalae
(Horváth et al., 1997).
While NMDAr function has been well-described in neurons,
its function in glial cells such as astrocytes and oligodendrocytes
still needs clarification despite intensive investigation over the
past 10 years (Salter and Fern, 2005; Cao and Yao, 2013).
This is likely to provide further insights into the pathways
affected in schizophrenia, given the role of oligodendrocytes
in the establishment and course of the disease (Cassoli
et al., 2015). Cultured oligodendrocytes present glutamate-
responsiveness to NMDAr, and may even release glutamate
in certain conditions (Deng et al., 2003). This enables
the study of the molecular mechanisms of oligodendrocytes
in vitro.
One way of modulating NMDAr function in experimental
settings is by employing pharmacological interventions. MK-801
(or [5R,10S]-[+]-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclo
hepten-5,10-imine or Dizocilpine) is a compound that belongs
to the secondary bicyclic amine class and acts as non-
competitive NMDAr antagonist, not only in neurons, but
also in oligodendrocytes (Li et al., 2013). This compound
binds to two sites on the NMDAr-ion channel complex in
a manner similar to phencyclidine (PCP; Kornhuber et al.,
1989) in vivo and in vitro (Murray et al., 2000). The NMDAr
mediates glutamatergic transmission and plays a key role in
neural plasticity of central nervous system (CNS; Harrison and
Weinberger, 2004).
Besides the neuroprotective effects observed in stroke, trauma,
Parkinson and organophosphate-induced seizure models, MK-
801 also induces schizophrenia-like symptoms (Kovacic and
Somanathan, 2010) such as alterations in prepulse inhibition
(PPI; Zangrando et al., 2013). This has led researchers to employ
MK-801 as a pharmacological model of schizophrenia (Paulson
et al., 2007) for testing effects of antipsychotics such as clozapine
(Paulson et al., 2007; Zuo et al., 2009; Vardigan et al., 2010; Brown
et al., 2014).
Previous studies have shown that the NMDAr is also
present in oligodendrocytes (Simon et al., 1984; Karadottir
et al., 2005; Salter and Fern, 2005; Micu et al., 2006) and
may be involved in regulation of myelination processes (Li
et al., 2013). NMDA receptor signaling in oligodendrocytes also
plays a crucial role in their energy metabolism and regulates
differentiation and migration of these cells (for review see
(Cao and Yao, 2013). Here, we have carried out a quantitative
proteomic analysis to analyze protein expression changes in
the human oligodendrocyte hybrid cell line (MO3.13) following
treatment with MK-801 or the antipsychotic clozapine compared
to control cells. The main objective was to shed light on
the biochemical mechanisms involving NMDAr function in
oligodendrocytes in order to determine whether these cells
could be useful in future studies to model some aspects of
schizophrenia.
EXPERIMENTAL PROCEDURES
Cell Cultures, Treatments, and Proteome
Extraction
MO3.13 cells were maintained in DMEM medium supplemented
with 2 mM L-glutamine, 1% penicillin/streptomicyn (Sigma-
Aldrich, St. Louis, MO, USA) and 10% heat-inactivated fetal
bovine serum (Life Technologies, Darmstadt, Germany), at 37◦C
in humidified atmosphere containing 5% CO2, as described
previously (Iwata et al., 2013). Cells were treated once and
collected after 8 h as follows: Group 1 – 50 mM MK-801; Group
2 – 50 mM MK-801 plus 50 mM clozapine after 4 h; Group
3 – 50 mM clozapine; Group 4 – vehicle solution (0.01 M
HCl; Figure 1). The glycine (0.4 mM) and glutamate (20 uM)
contained in DMEM and FBS respectively are sufficiently high
to activate NMDA receptors (Blanke and VanDongen, 2009;
Cummings and Popescu, 2015).
MO3.13 cells were centrifuged at 1,000 g for 3 min and the
pellets homogenized in 50 µL of 7 M urea, 2 M thiourea, 4%
CHAPS, 2% ASB-14, and 70 mM DTT using a sample grinding
kit (GE Healthcare, Uppsala, Sweden; Martins-de-Souza et al.,
2007). Protein lysates were centrifuged for 10 min at 13,800 g, the
supernatants collected and protein concentrations determined by
Bradford assay (Bio-Rad, Munich, Germany).
ICPL (Isotope-Coded Protein Labeling)
Labeling
Cell lysate proteins were labeled with ICPL reagent from SERVA
ICPLTM Quadruplex Kit (SERVA Electrophoresis, Heidelberg,
Germany), as previously described (Maccarrone et al., 2014).
Equal amounts of light and heavy labeled samples were combined
and separated by 12% SDS gel electrophoresis before brilliant
Coomassie staining. After staining, each gel lane was sliced in
10 pieces and the protein bands were digested in-gel using
a 1:80 ratio of trypsin:ammonium bicarbonate. The resulting
peptides were dried and stored at −80◦C prior to shotgun mass
spectrometry analyses.
NanoLC-ESI MS/MS, Data Processing
and Database Searching
Extracted peptides were dissolved in 0.1% formic acid aqueous
solution and analyzed using a 2D-nano-LC system (Eksigent,
Dublin, CA, USA) coupled online to an LTQ-Orbitrap XL
mass spectrometer (Thermo Scientific, Bremen, Germany), as
previously described (Maccarrone et al., 2013). The MS/MS
fragmentation spectra were acquired in data dependent mode,
and the five most intense signal ions (m/z) in each scan were
selected for fragmentation. Nanoflow LC–MS/MS was performed
in automatic mode via Xcalibur software (version 2.0.7, Thermo
Scientific, San José, CA, USA). Each gel slice generated one MS
raw data file, which was processed for generation of the.mgf
file. The target and decoy (reverse sequence) databases were
searched using the UniProt human protein database (release 2013
08, 20,266 sequences) through the Mascot server. The search
parameters were (1) peptide and fragment ion mass accuracy
10 ppm and 0.5 Da, respectively, (2) protein and peptide FDRs
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FIGURE 1 | Experimental setup. Briefly, MO3.13 cells were grown in the presence of MK-801 or clozapine or MK-801/clozapine. Proteins were extracted, labeled
with ICPL and mixed with the same peptide amount. To reduce the proteome complexity, the samples were prior fractionated by SDS-PAGE, and protein bands
were digested by trypsin at room temperature. In last step, the proteins from each gel slice were then subjected to LC-MS/MS analyses.
1%, (3) two missed cleavages, (4) trypsin as enzyme, (5) fixed
modification = cysteine carbamidomethylation and variable
modification=methionine oxidation and ICPL labeling.
Proteome Quantification
Identified proteins had to fit the following criteria in all
analyzed datasets to be considered for quantification as described
previously (Maccarrone et al., 2014): (1) identification by at
least 2 non-redundant peptides; (2) fold changes not greater
than ±15; and (3) the standard deviation of quantified
peptides not greater than 10. Determination of isotope-labeled
peptide ratios was performed with MASCOT Distiller (Matrix
Sciences). The software calculates the fold-changes of each
identified peptide, considering the signal intensities of the
same peptide across different samples. The fold changes
of all peptides of a given protein were averaged, thereby
determining the protein fold change. Based on our previous
results (Maccarrone et al., 2014), we only considered proteins
differentially expressed if they presented a fold-change greater
than ±1.5 and proteins with fold changes between 1.5 and
2 were only considered if quantified by at least 5 peptides.
In addition, all quantitated proteins were required to have
a normal distribution at the peptide level, as determined by
the Shapiro–Wilk W-test so an analysis of variance (ANOVA)
could be employed to determine differentially expressed proteins.
Only those with p-values lower than 0.05 were considered
further.
Pathway and Functional Correlation
Analysis
The Uniprot accession codes of differentially expressed proteins
were mapped to Gene Ontology (GO) categories (biological
function and molecular process), using a script linked to the
Human Protein Reference Database1. The same codes were
also uploaded into the QIAGEN Ingenuity R© Pathway Analysis
software (IPA R© , QIAGEN, Redwood City, CA, USA2), to the
associated over-represented biological pathways and functions.
IPA core analysis was performed using experimentally observed
data from human and CNS cell lines, with canonical pathways,
diseases and biological functions, and networks explored in
detail. The refinement of the network generated by IPA was
performed applying the following parameters: (1) direct/indirect
interactions, (2) experimentally observed as confidence level,
1http://www.hprd.org/
2www.qiagen.com/ingenuity
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(3) human as species, (4) tissues/cell lines, and (5) disease related
to the CNS.
Western Blot
MO3.13 protein lysates were (20 µg) were electrophoresed on
12% sodium dodecyl sulfate (SDS) minigels prepared in house.
Proteins were transferred to Immobilon-FL polyvinyldiphenyl
fluoride (PVDF) membranes (Millipore; Bedford, MA, USA) at
100 V for 1 h using a cooling system. PVDF membranes were then
treated with 5% Carnation instant non-fat dry milk powder in
Tris buffered saline (pH 7.4) containing 0.1% Tween -20 (TBS-T)
for 4 h and rinsed in TBS-T three times for a total of 20 min.
Membranes were incubated with Anti-Glutamate Receptor
NMDAR1 (NR1) antibody produced in rabbit at a dilution of
1:000 in TBS-T overnight at 4◦C (Sigma-Aldrich; Taufkirchen,
Germany). Membranes were then washed twice with TBS-T for
15 min per wash. Next, the membranes were incubated with anti-
c-MYC-peroxidase antibody (GE Healthcare; Uppsala, Sweden)
for 40 min at room temperature, washed with water and TBS-T,
and incubated with enhanced chemiluminescence (ECL) solution
(GE Healthcare) for 1 min. The membranes were scanned using a
Gel DocTM XR+ System (Silk Scientific Incorporated; Orem, UT,
USA) and the optical densities of the immunoreactive bands were
measured using Quantity One software (Bio-Rad; Figure 2).
FIGURE 2 | N-methyl-D-aspartate (NMDA) receptor Western Blot in
MO3.13 protein lysates.
RESULTS
All treatments here studied (MK-801, MK-801+Clozapine
and only clozapine) modified the proteome of cultured
oligodendrocytes. The differentially expressed proteins were
analyzed in terms of their biological processes, and the result
is shown in Figure 3. All three analyzed proteomes presented
differences in similar biological processes. For instance, proteins
associated to protein metabolism were the most prevalent on
all three different treatments in percentage terms. On the other
hand, there are proteins and functional correlations, which are
specifically modulated by each different treatment analyzed.
MK-801-Treated Oligodendrocytes
MK-801 treatment for 8 h induced changes in the levels of 68
proteins in cultured oligodendrocytes (Supplementary Table S1).
These proteins are mostly associated with energy metabolism
functions and included aldolase A (ALDOA), aldolase C
(ALDOC), malate dehydrogenase (MDH2), and transketolase
(TKT; Table 1). In addition, proteins such as prohibitin
(PHB) and annexin 5 (ANXA5), which are associated with
communication and cell signaling, and the protein metabolism-
related proteins nucleophosmin (NPM1), 40S ribosomal protein
S16 (RPS16) and 60S ribosomal protein L7A (RPL7A), were
specifically altered by the MK-801 treatment.
MK-801-Treated Oligodendrocytes with
Added Clozapine
The addition of clozapine after 4 h to the MK-801-treated
cells affected the expression levels of 45 proteins, involved in
six different biological processes. Most of these proteins are
associated with energy metabolism, oxidative stress, and protein
metabolism, and included changes in ALDOA, peroxiredoxin-6
(PRDX6), NPM1 and RPS16. In addition, profilin-1 (PFN1), a
protein associated with cell growth and maintenance, showed the
highest fold change of the proteins in this group (Supplementary
Table S2).
Clozapine-Treated Oligodendrocytes
Treatment with clozapine alone induced alterations in the
levels of 122 proteins in cultured oligodendrocytes. Clozapine
treatment mostly induced changes in proteins associated with
regulation of nucleic acid metabolism, such as histone H2B
(HIST1H2BJ), polyadenylate binding protein (PABPC1), and
ribonucleoprotein (SNRPA1). In addition, ribosomal proteins as
L32 (RPL32) and L8 (RPL8) were also affected (Supplementary
Table S3). These effects are likely to represent early changes in
the transcriptional and translational machinery as part of the
clozapine response in oligodendrocyte cells.
In silico Systems Biology
In silico analysis was performed using IPA, inputting the
accession codes of the differentially proteins modulated in each
treatment group. The results are shown in Figure 4. Essentially,
the obtained proteomes were associated with some canonical
pathways, biofunctions, disorders, and toxicities.
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FIGURE 3 | Biological processes involving the proteins identified with MK-801, Clozapine, and concomitant (MK-801 and Clozapine) treatment. Bars
in dark blue, blue, and light blue depict MK-801, Clozapine and MK-801/Clozapine treatments, respectively.
Among the canonical pathways, proteins altered in the MK-
801-treated cells were related to cell signaling pathways mediated
by 14-3-3 protein kinase, p70S6K and by the factor eIF2 at
approximately equal levels. In contrast, the proteins altered
by clozapine treatment showed a marked relationship to eIF2
signaling, followed by 14-3-3-mediated and p7056k signaling.
The proteome changes in MK-801-treated oligodendrocytes with
the addition of clozapine showed effects similar to the MK-801
treatment alone with additional changes in proteins involved in
carbohydrate metabolism pathways (Figure 4A).
The MK-801 treatment resulted in similar values for all groups
in the area of biofunctions and disorders, except for neurological
disorder group, which showed the highest score. However, the
altered proteins in the clozapine-treated cells were linked with
neurological disease as well as psychological, and skeletal and
muscular disorders (Figure 4B).
Toxicity pathways generated by the analysis were associated
mainly with NRF2 oxidative stress and cell cycle G2/M DNA
damage responses in the clozapine treatment group (Figure 4C).
Furthermore, the proteome changes associated with the MK-
801 treatment were mainly linked to reduction of mitochondrial
membrane permeability, oxidative stress, and cell cycle G2/M
DNA damage responses.
The list of altered proteins from the MK-801 treatment was
also analyzed in terms of protein networks generated by the
IPA software. This analysis can identify binding or interacting
proteins which have not been detected by the proteomic
approach (Figure 5). Hypoxia-inducing factor 1-α (HIF1-α),
endothelial PAS domain-containing protein 1 (EPAS1), and
MYC-proto-oncogene protein (MYCN), were the most associated
transcription factors. In addition, proteins involved in energy
metabolism, kinases, and heat shock proteins (HSPs) were the
highly represented in the network generated (Figure 5).
DISCUSSION
One of major challenges in neuropsychiatric research is the
relatively limited knowledge of the molecular mechanisms of
these diseases. The development of new preclinical models to
improve such knowledge is also challenging for the same reasons.
Biological assays using animals or cellular cultures as models are
still emerging, with the aim to provide more information about
the acute effects caused by administration of neuromodulators
such as MK-801 and antipsychotic drugs (Paulson et al., 2004,
2007; Ji et al., 2009a,b; Ma et al., 2009; Martins-de-Souza
et al., 2011b; Ahmed et al., 2012; Palmowski et al., 2014).
Considering the known effects of oligodendrocyte dysfunction
in schizophrenia, we have investigated the acute response of
oligodendrocytic cells to the NMDA receptor antagonist MK-801
and clozapine treatment, by identification of protein abundance
changes using quantitative mass-spectrometry based proteomics.
Analysis of quantitative data allowed the identification of proteins
linked to a series of cellular processes and functions affected by
MK-801 and showed how clozapine may block the effects of
MK-801 in oligodendrocytic cells.
Biological Process
Taken together, the different treatment groups resulted in
changes in the levels of more than 200 proteins. Further studies
are warranted to determine whether or not those proteins
modulated by the MK-801 treatment are linked in any way
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to schizophrenia. This would help to establish the validity of
MK-801-treated oligodendrocytes as a potential model of some
aspects of schizophrenia. On the other hand, some of the proteins
modulated by the clozapine treatment may be biomarkers of
drug response and some could provide links to novel therapeutic
targets. The combined 200 proteins were mainly associated to
“cell communication and signaling,” “energy metabolism,” “cell
growth and maintenance,” “protein metabolism,” and “regulation
of nucleic acid metabolism” in terms of biological processes
(Figure 3). Several of these proteins have also been reported to be
differentially expressed in brain tissue samples of schizophrenia
patients (Nascimento and Martins-de-Souza, 2015) and in
animals treated with such drugs (Paulson et al., 2004, 2007; Ji
et al., 2009a,b; Ma et al., 2009; Palmowski et al., 2014). Similarly,
a previous proteomic analysis was performed to understand the
effects of MK-801 on cultured astrocytes (Martins-de-Souza et al.,
2011b).
In the present study, proteins associated to energy metabolism
were mostly upregulated in the MK-801 treated oligodendrocyte
cell line (Supplementary Table S2). This effect is consistent with a
number of studies which have used NMDAr antagonist treatment
to investigate its effects on neuronal cell cultures (Guest et al.,
2015) and rat brains (Paulson et al., 2004, 2007; Zhou et al.,
2012). Similar effects have been also been reported in proteomic
and transcriptomic studies using post-mortem samples from
schizophrenia patients (Martins-de-Souza, 2010; Martins-de-
Souza et al., 2011a; Cassoli et al., 2015). Taken together, these
findings suggest that dysfunctions of NMDA activity can cause
disruptions in energy metabolism pathways and vice-versa.
However, further studies are necessary to extrapolate these
findings to schizophrenia pathophysiology.
Effects of clozapine on cell cultures have already been
reported. This drug induced oxidation of proteins involved
in energy metabolism in SKNSH neuroblastoma cells,
seen as effects on mitochondrial ribosomal protein S22
(MRPS22), mitochondrial malate dehydrogenase (MDH),
calumenin (CALU), pyruvate kinase (PK1), and 3-oxoacid
CoA transferase (OXCT1; Walss-Bass et al., 2008). Likewise,
this antipsychotic provoked an increased oxidation of specific
proteins, such as enolase (ENO), triosephosphate isomerase
(TPI), glyceraldehyde-3-phosphate dehydrogenase (GAPD),
Rho GDP dissociation inhibitor (GDI), cofilin (CFL), uridine
monophosphate/cytidine monophosphate (UMP-CMP) kinase,
and translation elongation factor, in lymphoblastoid cells
obtained from patients with schizophrenia compared to those
from healthy subjects (Baig et al., 2010). In this study, we also
found that clozapine influenced the expression levels of proteins
from the same biological processes in oligodendrocyte cells.
Effects of Clozapine on MK-801-Treated
Cells
Treatment with clozapine appeared to reverse some of the
proteome changes caused by the MK-801 treatment, suggesting
that such proteins might be associated with the medication
response. Additionally, 16 proteins were affected in a similar
manner in all three treatment groups (Table 1; Figure 6). Some
FIGURE 6 | Venn diagram. Protein overlap between the three drug
treatments (MK-801, Clozapine, and MK-801, and Clozapine) applied to the
characterization of oligodendrocyte proteomes.
of these proteins showed opposite directional changes depending
on whether cells were treated with MK-801, clozapine or both.
This suggests that these proteins may be involved in both the
pathophysiology and the medication response. Such proteins
included the AKAP10, ALDOC, protein disulfide isomerase
family A member 3 (PDIA3), PHB, Rab GDP dissociation
inhibitor beta (GDI2), and PRDX6 (Table 1), which are discussed
below.
AKAP10 levels were increased by the MK-801 treatment and
decreased by clozapine. The AKAP family of scaffold proteins are
a diverse group of functionally related proteins that anchor the
cAMP-dependent protein kinase (PKA) as well as other signaling
proteins to coordinate signal transduction in different subcellular
locations (Sanderson and Dell’Acqua, 2011). They have also
been associated with synaptic plasticity, which is induced by
activation of NMDA-type glutamate receptors. This suggests that
clozapine may act on processes related to synaptic plasticity via
effects on AKAP10. Moreover, this protein has been found to
be differentially expressed in samples of corpus callosum from
schizophrenia patients (Saia-Cereda et al., 2015).
Aldolase C has been previously reported to be upregulated
in the frontal cortex (FC), insulate cortex (IC) and dorsolateral
prefrontal cortex (DLPFC) and downregulated in the prefrontal
cortex (PFC), Wernicke’s area (WA), anterior temporal lobe
(ATL) and anterior cingulate cortex (ACC) of schizophrenia
patients compared to controls (Martins-de-Souza et al., 2011a).
ALDOC is a glycolytic enzyme that catalyzes the reversible aldol
cleavage of fructose-1,6-biphosphate and fructose 1-phosphate to
produce dihydroxyacetone phosphate and either glyceraldehyde-
3-phosphate or glyceraldehyde, respectively. In the present study,
we found that the clozapine co-treatment resulted in a lowering
of ALDOC levels in relation to increased levels induced by the
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FIGURE 4 | IPA analysis of proteomic data arisen each drug treatment. (A) Canonical pathways, (B) related disorders and Biofunctions, and (C) toxicity
pathways generated from IPA analysis. Bars in dark blue, blue, and light blue depict MK-801, Clozapine and MK-801/Clozapine treatments, respectively.
MK-801 treatment. Disturbances in ALDOC expression, and
expression of the ALDOA isoform have also been reported by
studies involving MK-801-treated animals and astrocyte cultures
(Paulson et al., 2004; Martins-de-Souza et al., 2011b).
Clozapine treatment resulted in increased levels of PDIA3,
a protein belonging to a family of enzymes that introduces
disulfide bonds into proteins and catalyzes rearrangement of
incorrect disulfide bonds (Wilkinson and Gilbert, 2004). Distinct
from the present result, protein previous study showed that
PDIA3 was downregulated after treatment of astrocytes with
MK-801 (Martins-de-Souza et al., 2011b). This suggests that
MK-801 and clozapine may have opposite effects on PDIA3
levels in oligodendrocytes and astrocytes. The MK-801 treatment
promoted an upregulation of PHB in oligodendrocytes, which
was similarly upregulated in the DLPFC and ACC, and decreased
in the PFC of schizophrenia patient brain samples (Smalla et al.,
2008; Martins-de-Souza et al., 2010). PHB is a multifunctional
protein which acts as a chaperone for respiration chain proteins,
a general structuring scaffold in mitochondrial morphology,
and it is involved in cell proliferation and transcriptional
modulation (Zhou and Qin, 2013; Peng et al., 2015). Rats
treated with ketamine – another NMDAr antagonist – have also
shown PHB upregulation in post-synaptic density preparations
of DLPFC from chronic schizophrenia patients (Smalla et al.,
2008). Oligodendrocytes isolated from the DLPFC have also been
found to have increased levels of PHB (Bernstein et al., 2012).
Likewise, a recent proteomic study showed PHB upregulation in
the peripheral blood serum and brain tissue from rats acutely
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FIGURE 5 | Potential network interactions, and their interactors, of differentially expressed proteins of MK-801-treated oligodendrocytes. The network
was generated from differentially expressed proteins by IPA (see “Pathway and Functional Correlation Analysis”). Colored interactors represent proteins previous
found in the proteome. Full and dashed lines depict direct and indirect connections respectively.
treated with ketamine (Wesseling et al., 2015). Taken together,
these findings indicate a relationship of PHB increased expression
and hypofunction of NMDA receptor signaling.
Although, the Rab GDP dissociation inhibitor beta (GDI2)
has not been found to be altered in schizophrenia proteomic
studies, the Rab GDP dissociation inhibitor alpha (GDI1) isoform
was previously found to be upregulated in samples of ACC
and DLPFC of schizophrenia patients (English et al., 2009;
Martins-de-Souza et al., 2010). The Rab proteins belong to the
GDP dissociation inhibitor protein family, which regulates the
GDP-GTP exchange reaction of members of small GTP-binding
proteins. They are mainly involved in vesicular trafficking of
molecules between cellular organelles (Shisheva et al., 1994).
In our results, GDI2 was oppositely regulated by MK-801 and
clozapine. However, addition of the antipsychotic to the MK-
801-treated cultures was not sufficient to completely block GDI2
upregulation.
Another protein modulated by both MK-801 and clozapine
in oligodendrocytes was peroxiredoxin 6 (PRDX6). The
peroxiredoxins are a family of antioxidant enzymes that are
ubiquitously distributed in the cell and can control cytokine-
induced peroxide levels, which mediate signal transduction
in mammalian cells. High abundance of peroxiredoxins in
mammalian cells appears to protect the cellular components by
removing accumulated peroxides produced as a result of normal
cellular metabolism or as a response to oxidative stress (Rhee
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et al., 2005). In our study, PRDX6 was found to be upregulated by
MK-801 and the clozapine single treatments. Interestingly, this
effect was enhanced by the co-treatment resulting in markedly
higher levels of this protein. PRDX6 has also been found to be
altered in DLPFC and WA from schizophrenia patients (Martins-
de-Souza et al., 2009a,b) as well as in MK-801-treated astrocytes
(Martins-de-Souza et al., 2011b). An upregulation of PRDX6
following haloperidol treatment in rats has also been described
(Andreazza et al., 2015), although the same study suggested that
clozapine may also induce oxidative stress in liver, consistent with
the documented adverse effects of this drug. Taken together, these
findings show a potential connection between neurotransmission
dysfunctions and oxidative damage, which might be relevant
to disease pathogenesis (Ben-Shachar and Laifenfeld, 2004;
Rajasekaran et al., 2015). Furthermore, the phospholipase
A2 (PLA2) activity of PRDX6 is critical for regulation of
phospholipid turnover (Chen et al., 2000) and differential
regulation of PRDX6 may accelerate phospholipid turnover.
Both of these PRDX6 activities may be related to schizophrenia
pathogenesis since an enhancement of phospholipid turnover
has been previously reported in schizophrenia frontal lobe
(Gattaz et al., 1990). Therefore, PRDX6 could function as a brain
marker for schizophrenia.
In silico Functional Correlations
Functional correlation of the regulated proteins revealed that
MK-801 and clozapine treatment could lead to alterations in the
canonical signaling pathways mediated by 14-3-3 protein kinase,
p70S6K and eIF2 factor. In addition, changes in carbohydrate
metabolism pathways were also detected.
The 14-3-3 proteins compose a family of highly conserved
acidic proteins, with molecular weights of 25–30 kD. There are
seven mammalian 14-3-3 isoforms in eukaryotic cells which
function as adaptor or “chaperone molecules” and scaffolding
proteins that can translocate freely from the cytoplasm to the
nucleus and vise-versa (Muslin et al., 1996). They are found
as homo- or heterodimers and interact with cellular proteins
representing a wide range of processes, such as neuronal
development, mitogenic signal transduction, apoptotic cell death,
cell cycle and cell growth controls (Mhawech, 2005). Several
reports have shown disturbances in the expression of this protein
family in schizophrenia brain tissue (Hayakawa et al., 1998;
Wong et al., 2003; Middleton et al., 2005; Martins-de-Souza
et al., 2012; Saia-Cereda et al., 2015; Schubert et al., 2015).
Moreover, schizophrenia-related behavioral phenotypes have
been described in 14-3-3 functional knockout mice (Cheah et al.,
2012; Foote et al., 2015). Here, MK-801 and clozapine treatments
resulted in increased levels of 14-3-3 proteins. Interestingly, when
clozapine was administered to MK-801-treated cells, the levels of
14-3-3 protein theta (14-3-3ζ) decreased and signaling mediated
by the 14-3-3 family appeared to be abolished. Other studies have
described changes in this protein family in the PFC of subjects
with schizophrenia as a normalizing effect of antipsychotics,
such as clozapine (Rivero et al., 2015). Furthermore, clozapine
has been used to rescue the locomotor hyperactivity of 14-3-
3ζ knockout mice, which may indicate a novel role for 14-3-
3ζ in dopaminergic neurotransmission (Ramshaw et al., 2013).
Considering these findings, further studies should be performed
to determine whether or not dysregulation of 14-3-3 expression
in oligodendrocytes is involved in schizophrenia, as suggested in
by some post-mortem studies.
A previous study reported a decrease in phosphorylation
of p70S6K and its substrates in frontal cortices of 7-days-old
rats that were acutely treated with MK-801 (Yoon et al., 2008).
Although, MK-801 is an NMDAr antagonist, the present results
indicated that it may also antagonize p70S6K signaling. In
contrast, the clozapine and co-MK-801/clozapine co-treatment
led to increased expression of proteins involved in p70S6K
signaling. The p70S6K protein is a serine/threonine kinase
that phosphorylates the ribosomal S6 subunit, a component
of the 40S subunit of eukaryotic ribosomes. It is activated by
mTOR in mitogenic pathways downstream of phosphoinositide
3 kinase (PI3K) and plays a role in protein synthesis and in cell
growth control (Fenton and Gout, 2011). Thus, the observed
upregulation of the p70S6K pathway promoted by MK-801
and clozapine in oligodendrocytes might represent an adaptive
response resulting in increased translation initiation in protein
synthesis.
The initiation phase of protein synthesis, during which
ribosomes select mRNAs to be translated, and identify the
translational start site, requires a set of EIFs (eukaryotic
translation initiation factors). EIF2 (eukaryotic initiation
factor-2) is a GTP (guanosine triphosphate)-binding protein that
enables transport of the initiation-specific form of Met-tRNA
(Met-tRNAi) onto the ribosome. According to IPA analysis,
all drug treatments affected the expression of many proteins
related to EIF2 signaling in oligodendrocytes. This effect
seems to activate the pathway and may reflect the increased
protein synthesis in the cells. Members of EIFs have been
found functionally linked to the disrupted in schizophrenia 1
protein (DISC1) and to stress granules (Ogawa et al., 2005).
Moreover, many risk-promoting genes and a number of
environmental risk factors are related to oligodendrocyte cell
loss and hypomyelination via activation of EIF2-alpha kinases
in schizophrenia (Carter, 2007). These can lead to an arrest of
protein synthesis through the eventual inhibition of translation
initiation factor EIF2-beta by phosphorylated eIF2-alpha (Carter,
2007).
Toxicity Pathways
The toxicity pathways associated with the proteomic changes of
all treatment groups were mainly cell cycle G2/M DNA damage
and nuclear factor-erythroid 2-related factor 2 (NRF2)-mediated
responses. The link to cell cycle G2/M DNA damage signaling was
due to changes in the 14-3-3 family proteins (YWHAB, YWHAG,
YWHAH, YWHAQ, and YWHAZ), in addition to the Wee1-like
protein kinase (WEE1).
Other proteins predicted to be involved in drug treatment
responses included alcohol dehydrogenase [NADP(+)]
(AKR1A1), T-complex protein 1 subunit eta (CCT7), DnaJ
homolog subfamily B member 11 (DNAJB11), dual specificity
mitogen-activated protein kinase kinases 1 (MAP2K1) and
2 (MAP2K2), although this occurred most predominantly in
the MK-801 and clozapine co-treatment condition. NRF2 is a
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reactive oxygen species-responsive transcription factor, which
binds to the antioxidant response elements (AREs) within
the promoter of antioxidant enzyme genes and activates their
transcription. NRF2 signaling takes place upon exposure of cells
to oxidative stress through phosphorylation of the protein in
response to activation of protein kinase C, phosphatidylinositol
3-kinase and MAP kinase pathways (Petri et al., 2012). After
phosphorylation, NRF2 translocates to the nucleus, binds
AREs and transactivates detoxifying enzymes and antioxidant
enzymes, such as glutathione S-transferase, NAD(P)H quinone
oxidoreductase, sulfiredoxin 1 (SRXN1) and thioredoxin
reductase 1 (TXNRD1). SRXN1 and TXNRD1 are involved
in the reduction and recovery of peroxiredoxins (Neumann
et al., 2009; Soriano et al., 2009). The current results suggest
that differential expression of NRF2 signaling proteins can
affect PRDXs expression, although additional analyses should
be performed to confirm these findings.
Potential Interactions
The analysis of potential protein interactions showed that MK-
801 treatment of oligodendrocytes included changes in proteins
linked to other proteins which were mostly associated with energy
and protein metabolism. However, nuclear transcription factors
also appeared as highly connected proteins such as hypoxia-
inducing factor 1-α (HIF1-α), MYCN and endothelial PAS
domain-containing protein 1 (EPAS1). This suggests that these
factors may be upstream regulators of the energy metabolism
proteins altered by the MK-801 treatment.
HIF1-α is a subunit of a heterodimeric transcription factor
hypoxia-inducible factor 1 (HIF-1) encoded by the HIF1A gene.
HIF1 is the main transcriptional factor regulating the effects
of hypoxia in expression of genes for angiogenesis, glycolysis
and protective responses (Semenza, 2001). This factor is
important in embryonic development and neural fold formation
(Maltepe and Simon, 1998). Moreover, HIF1 has been related
to regulation of many risk genes of schizophrenia. A meta-
analysis study revealed that more than 50% of schizophrenia
candidate genes met the criteria for a link to ischemia, hypoxia
and/or vascular factors (Schmidt-Kastner et al., 2012) and
epidemiological studies have shown that, events that lead
to development of fetal hypoxia and inflammation during
pregnancy are associated with increased risk of schizophrenia
later in life (Nicodemus et al., 2008; Khandaker et al.,
2013).
Final Remarks
Considering all findings discussed above, the current study
supports the concept that dysfunctions in NMDAr signaling in
oligoendrocytes may be a central process in schizophrenia. MK-
801-treated oligodendrocytes exhibited differences on cellular
processes that have been previously observed in schizophrenia
samples and have also revealed new pathways that could
be pivotal in the development of this disorder. Although,
the MK-801 treated oligodendrocyte model cannot reflect
the pathophysiology of a complex psychiatric disorder as
schizophrenia in its entirety, employing this approach might
provide insights about specific aspects of the disease and lead to a
novel preclinical tool for drug target discovery
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